1. Home
  2. STX vs AZN Comparison

STX vs AZN Comparison

Compare STX & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seagate Technology Holdings PLC (Ireland)

STX

Seagate Technology Holdings PLC (Ireland)

HOLD

Current Price

$853.50

Market Cap

182.2B

Sector

Technology

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$185.95

Market Cap

316.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STX
AZN
Founded
1978
1992
Country
Singapore
United Kingdom
Employees
N/A
96100
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.2B
316.4B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
STX
AZN
Price
$853.50
$185.95
Analyst Decision
Buy
Strong Buy
Analyst Count
21
1
Target Price
$604.14
N/A
AVG Volume (30 Days)
3.0M
1.7M
Earning Date
04-28-2026
04-29-2026
Dividend Yield
0.46%
1.73%
EPS Growth
328.48
N/A
EPS
8.29
N/A
Revenue
$7,384,000,000.00
N/A
Revenue This Year
$27.73
$10.34
Revenue Next Year
$25.06
$6.43
P/E Ratio
$111.85
$31.91
Revenue Growth
N/A
N/A
52 Week Low
$124.63
$68.62
52 Week High
$966.80
$212.71

Technical Indicators

Market Signals
Indicator
STX
AZN
Relative Strength Index (RSI) 58.33 49.81
Support Level $695.14 $180.98
Resistance Level N/A $191.50
Average True Range (ATR) 48.64 3.00
MACD -3.37 -0.05
Stochastic Oscillator 57.11 61.27

Price Performance

Historical Comparison
STX
AZN

About STX Seagate Technology Holdings PLC (Ireland)

Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: